US FDA approves Bayer’s finerenone for new indication in patients with heart failure with left ventricular ejection fraction of ≥ 40%: Berlin Wednesday, July 16, 2025, 13:00 H ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

The FDA has broadened the approved use of finerenone (Kerendia) to include treatment for heart failure, according to an ...

In a significant move, the U.S. Food and Drug Administration granted approval for Kerendia for patients with heart failure ...

Bayer’s Kerendia (finerenone) has been approved by the US Food and Drug Administration (FDA) to treat heart failure (HF) patients with left ventricular ejection fraction (LVEF) of at least 40%.

CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare ...

The era of predictive modeling enhanced with machine learning and artificial intelligence (AI) to aid clinical ...

This marks the second FDA-cleared ECG-AI device in Tempus’ cardiovascular product suite, following its previously cleared Tempus ECG-AF solution. The new software analyzes resting, non-ambulatory ...

CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) ...

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

Proper handling of continuous variables is crucial in healthcare research, for example, within regression modelling for descriptive, explanatory, or predictive purposes. However, inadequate methods ...